Synthesis, antibacterial and antioxidant activity of novel 12-(N-arylmethaniminyl)indolo[1,2-c]quinazolines

Aditya DIXIT 1 *, Devender PATHAK 2 ©, Gyanendra Kumar SHARMA 1 ©

1 Rajiv Academy for Pharmacy, Mathura, U.P., India
2 Pharmacy College, Saifai, Etawah, U.P., India
* Corresponding Author. E-mail: adixit70@gmail.com (A.D.); Tel. +919258474535.

Received: 05 October 2018 / Revised: 08 December 2018 / Accepted: 10 December 2018

ABSTRACT: The objective of the present research was to synthesize 12-(N-arylmethaniminyl)indolo [1,2-c]quinazoline derivatives (4a1-4a11) and further characterize in terms of 1H NMR, 13C NMR, FTIR and mass spectrophotometry. Evaluation of their antibacterial and antioxidant activity was also carried out. Most compounds have shown a good antioxidant activity in all the concentrations but compounds 4a7, 4a8 and 4a11 were found to be most potent antioxidants in comparison to others with an IC0 value of 18.78 ± 1.86 μg/ml, 16.84 ± 2.60 μg/ml and 18.64 ± 2.40 μg/ml respectively (DPPH method) and 18.83 ± 2.89 μg/ml, 16.61 ± 3.00 μg/ml & 16.8 ± 3.34 μg/ml respectively (H2O2 method). Antibacterial activity was done against B. subtilis and E. coli with the help of agar well diffusion method and it showed that all the derivatives in the series are having good antibacterial activity but compounds 4a9 and 4a11 were found to be most promising antibacterial agents. It was concluded that the compounds containing substituted anilines (4-nitro, 4-fluoro, 4-bromo and 4-chloro-2-nitro) on the methaniminyl group of 12th position of indoloquinazoline moiety have good antioxidant and antibacterial activities.

KEYWORDS: Synthesis; indoloquinazoline; antioxidant; antibacterial.

1. INTRODUCTION

If we talk about indole, then it is the most trusted component of the chemical constituents present in alkaloids [1, 2]. It consists of diverse pharmacological roles as well, for example antiviral activity [3-6], antiviral activity [7, 8], antimicrobial activities [9, 10], antitubercular activity [11], antioxidant activity and antifungal activity [12]. Antimicrobial and antioxidant activities are the most prominent activities of indole nucleus. Many chemical structures containing indole have been reported by the pharmaceutical chemists as antimicrobial and antifungal compounds. From all those structures, ethyl-3-indolylacrylate, 5-bromo-3-(2-cyanovinyl)indole and 3-(2-nitrovinyl)indole were those derivatives which were effective against varieties of microorganisms [13]. A concentration between 10-100 μg/ml was the highly effective in case of haloindoles. One research study illustrated that some 3-Acetyl-4,7-dihydroxy indoles were found to be active against Escherichia coli and Streptococcus pyogenes [14]. 1-Morpholinolo-3-carboxethoxy-5-hydroxy- 2-methylindole was found to be most potent derivative against Escherichia coli and Bacillus cirroflagellosus [15]. 1-(4-Phenyl) and (1-naphthyl-4H-1,2,4-triazole-5-thion-3-yl)indoles were reported as strong antibacterial and antifungal compounds [16]. Some thiosemicarbazide compounds containing indole moiety and their cyclic 1,2,4-triazole and 1,3,4-thiadiazole derivatives were reported to be selective against microbes and fungi [17]. Several derivatives of indole fused with different heterocycles were reported and their antimicrobial potential was also determined. Out of them, 4H-pyrano[2,3-f]indole, benztetrahydrocyclohept[1,2-b]indole, and 1-triazolylethylbenz[gl]indole derivatives were found to be most active [18-20]. On the other hand, indole is a promising moiety for free radical scavenging activity. Many evidences are there about the involvement of free radicals in a variety of diseases and pathophysiological events.

How to cite this article: Dixit A, Pathak D, Sharma G.K. Synthesis, antibacterial and antioxidant activity of novel 12-(N-arylmethaniminyl) indolo[1,2-c]quinazolines. J Res Pharm. 2019; 23(3): 584-595.

© 2019 Marmara University Press
ISSN: 2630-6344
https://doi.org/10.12991/jrp.2019.166

584
including inflammation, cancer, myocardial infarction, arthritis neurodegenerative disorders [21-23]. This serious involvement of free radical action on vital systems is a multiple complex aspect of their involvement in a series of inflammatory diseases [24] and diseases related to nutrition [25, 26]. There are so many anti-inflammatory agents which act through scavenging of free oxygen radicals [27,28]. There is production of large amount of free radicals during the process of inflammation, out of a wide range of radicals, reactive oxygen species (ROS) such as, superoxide radical (O2•−), hydrogen peroxide (H2O2), hypochlorous acid (HOCl), singlet oxygen and peroxyl radical, as well as reactive nitrogen species (RNS), like nitric oxide (NO) and peroxynitrite anion (ONOO−). Indeed, ROS and RNS are produced by the endothelial cells, Kupffer cells, neutrophils and macrophages as mechanism of defense in response to infections caused by foreign pathogens [29-32]. On the other hand, ROS are also produced in the process of inflammation as a consequence of COX enzyme activity. Mitochondria are also considered as a great source of ROS [33]. These ROS and RNS are attached with a wide variety of pathologies and disorders such as cancer, rheumatoid arthritis, atherosclerosis, Alzheimer and Parkinson disease, among others [34]. In way of exploring some more potential of indole moiety, synthesis of some novel Indolo[1,2-c]quinazoline derivatives (4a1-4a11) was carried out and their antibacterial and antioxidant activity was reported.

2. RESULTS AND DISCUSSION

2.1 Chemistry

In the starting of scheme, phenyl hydrazone of 2-Aminoacetophenone was synthesized by refluxing equimolar quantities of phenyl hydrazine and 2-Aminoacetophenone in acetic acid/ethanol mixture for 3 h. Then, 2-(2-aminophenyl)indole (1a) was synthesized by cyclization of phenylhydrazone of 2-Aminoacetophenone in the presence of phosphorous pentoxide and methanesulphonic acid. Further cyclization of 1a in presence of 90% Formic acid gave Indolo[1,2-c]quinazoline (2a). Compound 2a was allowed to undergo formylation by Vilsmeier–Haack Formylation to yield 12-formylindoloquinazoline (3a). Compound 3a reacted with substituted anilines to give 12-(N-aryl methaniminyl)indolo[1,2-c]quinazolines (4a1-4a11). As shown by Billimoria et al reaction scheme for the compounds 1a, 2a and 3a was utilized which is presented below (Figure 1) [35].

The characterization of compounds was done with the help of IR, 1H NMR, 13C NMR, mass spectral data, and elemental analysis. In the IR spectrum of compounds 4a1-4a11, the aromatic C-H stretching vibrations gave rise to a band at 3080-3019 cm⁻¹. Stretching bands for aliphatic C-H were observed in the region of 2958-2798 cm⁻¹. The C-Cl stretching bands were observed at 752-692 cm⁻¹. The stretching vibrations of nitro group gave rise to bands at 1554-1508 cm⁻¹ and 1360-1308 cm⁻¹. Stretching vibrations of C-F and C-Br were observed at 1292 cm⁻¹ and 551 cm⁻¹ respectively.

In the 1H NMR spectrum of compound 4a1-4a11, the signals due to the protons of the aromatic rings appeared between 7.00 and 9.23 ppm in the form of singlet, doublet, double doublet and multiplet. The signal due to the C-H proton of methaniminyl group was observed at 7.50 ppm as a singlet. Spectra of compounds showed the signal due to the proton of quinazoline ring at 9.23 ppm as a singlet.

In the 13C NMR spectra of all compounds, signals due to carbons present in aromatic rings were observed in the region 102-160.1 ppm. The signal due to the N-C=N carbon of quinazoline ring was observed at 136 ppm. The signal due to the carbon of C-Cl was observed at 127-135 ppm. The signal due to the C-F carbon appeared at 161.40 ppm. The signal due to the C-Br carbon appeared at 121.63 ppm. Mass spectral data and elemental analysis were complying with the structures of compounds. [M+2] peaks were found for compounds with Cl moiety.

2.2. Biological activities

All the newly synthesized indole derivatives (4a1-4a11) were screened for their antibacterial and antioxidant activity.

https://doi.org/10.12991/jrp.2019.166
J Res Pharm 2019; 23(3): 584-595

585
Synthesized compounds were not shown significant antibacterial activity at the concentration range of 10 to 30 μg/ml. So, the higher concentrations of compounds were used to evaluate antibacterial efficacy. As shown in observations (Table 1), compound 4a9 showed 11 mm and 18 mm zone of inhibition at 100 μg/ml and 150 μg/ml concentrations, respectively against B. subtilis. Compound 4a11 showed maximum antibacterial activity against E.coli at 100 μg/ml concentration (zone of inhibition 10 mm). Ciprofloxacin showed better antimicrobial activity against B. subtilis and E. coli at lower concentration (25 μg/ml).
Table 1. Zone of inhibition values for derivatives (4a1-4a11) at 100 μg/ml and 150 μg/ml.

| Compounds | Zone of inhibition (mm) |
|-----------|-------------------------|
|           | B. subtilis  | E. coli  |
|           | 100 μg/ml | 150 μg/ml | 100 μg/ml | 150 μg/ml |
| 4a1       | 0         | 5         | 0         | 7         |
| 4a2       | 3         | 9         | 5         | 10        |
| 4a3       | 2         | 10        | 8         | 11        |
| 4a4       | 4         | 9         | 6         | 12        |
| 4a5       | 2         | 6         | 6         | 10        |
| 4a6       | 10        | 13        | 11        | 15        |
| 4a7       | 4         | 10        | 8         | 13        |
| 4a8       | 6         | 12        | 9         | 15        |
| 4a9       | 11        | 18        | 10        | 16        |
| 4a10      | 8         | 14        | 11        | 17        |
| 4a11      | 9         | 16        | 10        | 17        |

Ciprofloxacin (25 μg/ml)  20         18

2.2.2. Antioxidant activities

DPPH radical scavenging activity

The newly synthesized compounds were screened for free radical scavenging activity by DPPH method. The samples were prepared at concentrations of 10, 20, 30, 40 and 50 μg/ml, and ascorbic acid was taken as standard. Compounds 4a7, 4a8 and 4a11 were found to have good scavenging activity with an IC50 value of 18.78 ± 1.86 μg/ml, 16.84 ± 2.60 μg/ml and 18.64 ± 2.40 μg/ml, respectively. The tabular representation of percentage of free radical scavenging activity is shown (Table 2).

H2O2 radical scavenging activity

Compounds were screened for free radical scavenging activity by H2O2 method. The samples were prepared at concentrations of 10, 20, 30, 40 and 50 μg/ml, and ascorbic acid was taken as standard. Compounds 4a7, 4a8 and 4a11 were found to have good scavenging activity with an IC50 value of 18.83 ± 2.89 μg/ml, 16.61 ± 3.00 μg/ml and 16.8 ± 3.34 μg/ml, respectively. The tabular representation of percentage of free radical scavenging activity is shown (Table 3).

2.3. Structure activity relationship

Above stated results showed that all those compounds which were having para substitutions, they were found to be potent antibacterials and antioxidants. Compounds 4a9 (4-Bromophenyl substituent) and 4a11 (4-Chloro-2-Nitrophenyl substituent) were found to be most promising antibacterials among all other synthesized compounds. Compounds 4a7 (4-nitrophenyl substituent), 4a8 (4-fluorophenyl substituent) and 4a11 (4-chloro-2-nitrophenyl substituent) were found to be most potent antioxidants due to the presence of electron withdrawing groups at para position. Another electron withdrawing group at ortho position can enhance the antioxidant activity, it can be clearly observed in case of compound 4a11 where nitro group is attached at ortho position along with chlorine atom at para position.
Table 2. DPPH free radical scavenging activity of compounds 4a1-4a11.

| Compounds | % Inhibition at µg/ml* |
|------------|------------------------|
|            | 10         | 20         | 30         | 40         | 50         |
| Ascorbic acid | 45.8 ± 1.21 | 54.01 ± 1.09 | 61.60 ± 0.98 | 66.89 ± 1.23 | 78.01 ± 2.31 |
| 4a1        | 04.21 ± 1.01 | 14.15 ± 0.95 | 24.69 ± 1.13 | 32.22 ± 1.15 | 39.45 ± 2.01 |
| 4a2        | 21.68 ± 1.10 | 29.21 ± 1.03 | 37.65 ± 1.22 | 39.45 ± 1.45 | 42.16 ± 2.32 |
| 4a3        | 17.16 ± 1.50 | 21.38 ± 1.16 | 26.20 ± 1.21 | 30.42 ± 1.33 | 36.74 ± 1.91 |
| 4a4        | 12.95 ± 1.41 | 20.18 ± 1.20 | 26.80 ± 1.27 | 31.02 ± 1.29 | 34.33 ± 1.80 |
| 4a5        | 09.03 ± 1.53 | 18.07 ± 1.62 | 24.69 ± 0.81 | 34.03 ± 1.16 | 45.78 ± 1.09 |
| 4a6        | 06.62 ± 1.21 | 12.95 ± 1.15 | 18.97 ± 0.99 | 23.49 ± 1.87 | 27.40 ± 2.03 |
| 4a7        | 45.83 ± 1.12 | 50.32 ± 1.30 | 54.48 ± 1.51 | 64.74 ± 1.03 | 71.47 ± 1.99 |
| 4a8        | 47.28 ± 1.31 | 51.50 ± 1.02 | 55.12 ± 1.56 | 61.44 ± 1.28 | 66.56 ± 1.27 |
| 4a9        | 16.86 ± 1.18 | 24.09 ± 1.26 | 27.40 ± 1.40 | 31.32 ± 1.29 | 35.24 ± 1.33 |
| 4a10       | 29.21 ± 1.52 | 31.92 ± 1.01 | 33.73 ± 1.25 | 36.74 ± 1.36 | 40.06 ± 1.40 |
| 4a11       | 45.48 ± 1.14 | 51.50 ± 1.26 | 55.12 ± 1.71 | 60.54 ± 1.21 | 67.46 ± 2.06 |

* n=3 (results are average of triplicate readings with standard deviation)

Table 3. H2O2 free radical scavenging activity of compounds 4a1-4a11.

| Compounds | % Inhibition at µg/ml* |
|------------|------------------------|
|            | 10         | 20         | 30         | 40         | 50         |
| Ascorbic acid | 44.35 ± 1.21 | 55.32 ± 1.34 | 62.09 ± 1.51 | 66.72 ± 1.10 | 77.02 ± 1.33 |
| 4a1        | 07.34 ± 1.14 | 17.10 ± 1.61 | 21.22 ± 1.24 | 35.43 ± 1.91 | 43.45 ± 1.99 |
| 4a2        | 20.41 ± 1.05 | 33.35 ± 2.01 | 42.56 ± 1.14 | 46.87 ± 1.82 | 55.96 ± 1.90 |
| 4a3        | 16.32 ± 1.76 | 24.55 ± 2.21 | 31.48 ± 1.88 | 41.09 ± 1.67 | 47.21 ± 1.62 |
| 4a4        | 20.76 ± 1.55 | 27.86 ± 1.91 | 32.99 ± 1.77 | 38.58 ± 1.24 | 44.67 ± 1.85 |
| 4a5        | 10.31 ± 1.36 | 22.84 ± 1.78 | 28.45 ± 1.82 | 37.50 ± 1.08 | 47.08 ± 1.19 |
| 4a6        | 03.23 ± 1.47 | 13.65 ± 1.39 | 20.88 ± 2.22 | 31.78 ± 1.29 | 36.66 ± 1.02 |
| 4a7        | 44.60 ± 2.01 | 51.25 ± 1.98 | 55.03 ± 1.96 | 65.62 ± 1.21 | 71.09 ± 0.92 |
| 4a8        | 46.65 ± 1.58 | 52.15 ± 1.21 | 56.23 ± 1.73 | 61.78 ± 1.56 | 67.34 ± 0.86 |
| 4a9        | 14.32 ± 1.25 | 22.49 ± 2.02 | 29.77 ± 2.05 | 33.54 ± 1.69 | 39.06 ± 1.41 |
| 4a10       | 28.21 ± 1.05 | 37.22 ± 1.99 | 41.42 ± 1.59 | 45.65 ± 2.13 | 50.62 ± 2.20 |
| 4a11       | 46.17 ± 2.09 | 52.45 ± 1.68 | 56.87 ± 1.12 | 61.22 ± 1.52 | 68.33 ± 1.28 |

* n=3 (results are average of triplicate readings with standard deviation)

3. CONCLUSION

Synthesis of some new 12-(N- arylmethaniminyl)indolo[1,2-c]quinazolines (4a1-4a11) was carried out and then they were characterized by the 1H NMR, 13C NMR, FTIR and mass spectrophotometry. They were evaluated for their potential as an antioxidant and an antibacterial. Most of them have shown good antioxidant potential in all the dilutions. Compounds 4a7, 4a8 and 4a11 were found to be most potent antioxidants. Antibacterial studies showed that the compounds 4a9 and 4a11 have exhibited good spectrum of antibacterial activity. With these results, it can be concluded that the compounds containing para substituted anilines (4-nitro, 4-fluoro, 4-bromo & 4-chloro-2-nitro) on the methaniminyl group of 12th position of indoloquinazoline moiety have good antioxidant and antibacterial activities. In future, proposed compounds may be analyzed using in- vivo model for better results.
4. MATERIALS AND METHODS

4.1. Chemistry

Purity determination of all the derivatives was done by TLC on pre-coated silica gel aluminum sheets (Type 60 GF254, Merck) and iodine vapors and UV-Lamp were used as detecting agents of spots. The melting point determination was done by melting point apparatus and all the melting points were uncorrected. The infrared (FT-IR) spectra were recorded on 470- Shimadzu FTIR spectrophotometer and all values of wavenumber were expressed in cm⁻¹. NMR spectra were measured in DMSO-δ6 as solvent at 300 MHz (1H NMR) and 75 MHz (13C NMR) on a BRUKER AVANCE-300 spectrometer using tetramethylsilane (TMS) as an internal standard. Chemical shifts (δ) are given in parts per million (ppm). Spin multiplicities are given as s (singlet), d (doublet), dd (double doublet), t (triplet) and m (multiplet). Mass spectra were obtained on Shimadzu 2010A LC-MS spectrometer. Elemental analysis was done on Elemental Vario EL III Carlo Erba 1108 and the values were within ±0.04% of the theoretical values.

Experimental procedure for the synthesis of 2-(2-Aminophenyl)indole (1a)

Phenyl hydrazone of 2-Aminoacetophenone was synthesized by refluxing equimolar quantities of phenyl hydrazine and 2-Aminoacetophenone in acetic acid/ethanol mixture for 3 h. Methanesulfonic acid (225 ml) was heated to 80 °C and phosphorus pentoxide (31.5 g) was added slowly to it with stirring until it dissolved completely (mixture A). The phenylhydrazone of 2-Aminoacetophenone (22.5 g) was slowly added to mixture A, maintaining the temperature between 80 and 100 °C. The solution was then further heated at 80 °C for 30 min. The reaction mixture was then cooled to room temperature and poured over crushed ice containing sodium hydroxide. The solid precipitate was filtered, washed with water, and dried to afford the crude product which was crystallized from ethanol.
(Yield: 18.77 g, 83.42%, M.p. 144-145 °C)

Experimental procedure for the synthesis of Indolo[1,2-c]quinazoline (2a)

In a beaker, 2-(o-Aminophenyl)indole (18 g) was added to formic acid (88%, 135 ml) and the solution was heated at 90 °C for 1 h. The reaction mixture was then cooled to room temperature and poured over crushed ice. The solid precipitate was filtered, washed with water, and dried to afford crude product which was crystallized from ethanol.
(Yield: 13.67 g, 72.48%, M.p. 202-203 °C)

Procedure for the synthesis of 12-Formylindolo[1,2-c]quinazoline (3a)

Vilsmeier–Haack formylation

Phosphorous oxychloride (10.66 g) was slowly added to N,N-Dimethylformamide (410 ml) at 0 °C and the solution was stirred for 15 min and was added drop wise to Indolo[1,2-c]quinazoline (13.67 g) and the mixture was stirred for a further 15 min and then refluxed for 30 min. It was then cooled to room temperature and poured over crushed ice. The precipitate was filtered, washed with water (3 x 100 ml) and boiled with aqueous sodium hydroxide (5%, 100 ml). The solid was then filtered, washed with water till free of alkali, and dried. The crude material was crystallized from methanol to give compound 3a.
(13.21 g, 84.95%, M.p. 230-232 °C)

General procedure for the synthesis of 12-(N-Arylthioiminyl)indolo[1,2-c]quinazolines (4a1-4a11)

A mixture of 12-Formylindoloquinazoline (1 g, 4.06 mmol) and anilines (4.06 mmol) in methanol was refluxed for 1 h. After cooling the mixture was poured on ice to give precipitate. The product was filtered, washed with cold water and recrystallized with ethanol. Percentage yield was found in between 80–90 %.

N-(H-indolo[1,2-c]quinazolin-12-yl)methylene)benzenamine (4a1)

Compound 3a (1g) was refluxed with Aniline (0.37 g).
(Yield: 1.17 g, 90%); M.p. 250-251 °C;

https://doi.org/10.12991/jrp.2019.166
J Res Pharm 2019; 23(3): 584-595
N-((1H-indolo[1,2-c]quinazolin-12-yl)methylene)-2-chlorobenzenamine (4a2)

Compound 3a (1g) was refluxed with 2-Chloroaniline (0.51 g).

(Yield: 1.18 g, 82%); M.p. 256-257 °C;

FT-IR (νmax, cm⁻¹) 3055 (Aromatic C-H str.), 2924 (Aliphatic C-H str.), 1602 (C=N str.), 1570,1525 (Aromatic C=C ring str.), 1365 (Aromatic C-N str.), 750 (C-Cl str.);

1H NMR (300 MHz, DMSO-d6) δ ppm: 7.00 (dd, 1H), 7.10 (dd, 2H), 7.20 (dd, 2H), 7.30 (t, 2H), 7.40 (d, 1H), 7.50 (s, 1H), 7.58 (d, 1H), 7.60 (d, 1H), 7.83 (dd, 1H), 7.84 (d, 1H), 8.01 (d, 1H), 9.23 (s, 1H); 13C NMR (75 MHz, DMSO-d6) δ ppm: 102.00, 111.24, 119.12, 120.12, 120.45, 122.21, 122.59, 125.22, 126.19, 127.32, 127.41, 127.82, 130.51, 131.43, 134.11, 135.42, 136.71, 144.34, 149.41, 150.45, 150.54, 150.14, 160.18; EIMS (m/z): [M]+ 355.35, [M+1]+ 356.37, [M+2]+ 357.13; Fragments: 217.20, 189.37, 163.24, 138.23, 109.25, 27.15; Anal. calcd. for C22H16N3Cl: C, 74.26; H, 3.97; N, 11.81. Found: C, 74.22; H, 3.95; N, 11.84.

N-((1H-indolo[1,2-c]quinazolin-12-yl)methylene)-3-chlorobenzenamine (4a3)

Compound 3a (1g) was refluxed with 3-Chloroaniline (0.51 g).

(Yield: 1.18 g, 82%); M.p. 254-255 °C;

FT-IR (νmax, cm⁻¹) 3056 (Aromatic C-H str.), 2929 (Aliphatic C-H str.), 1579 (C=N str.), 1500, 1458 (Aromatic C=C ring str.), 1326 (Aromatic C-N str.), 752 (C-Cl str.);

1H NMR (300 MHz, DMSO-d6) δ ppm: 7.00 (dd, 1H), 7.10 (dd, 2H), 7.20 (dd, 2H), 7.30 (t, 2H), 7.40 (d, 1H), 7.50 (s, 1H), 7.58 (d, 1H), 7.60 (d, 1H), 7.83 (dd, 1H), 7.84 (d, 1H), 8.01 (d, 1H), 9.23 (s, 1H); 13C NMR (75 MHz, DMSO-d6) δ ppm: 102.00, 111.24, 119.12, 120.12, 120.45, 122.21, 122.59, 125.22, 126.19, 127.32, 127.41, 127.82, 130.51, 131.43, 134.11, 135.42, 136.71, 144.34, 149.41, 150.45, 150.54, 150.14, 160.18; EIMS (m/z): [M]+ 355.35, [M+1]+ 356.37, [M+2]+ 357.13; Fragments: 217.20, 189.37, 163.24, 138.23, 109.25, 27.15; Anal. calcd. for C22H16N3Cl: C, 74.26; H, 3.97; N, 11.81. Found: C, 74.22; H, 3.95; N, 11.82.

N-((1H-indolo[1,2-c]quinazolin-12-yl)methylene)-4-chlorobenzenamine (4a4)

Compound 3a (1g) was refluxed with 4-Chloroaniline (0.51 g).

(Yield: 1.22 g, 85%); M.p. 250-251 °C;

FT-IR (νmax, cm⁻¹) 3041 (Aromatic C-H str.), 2894 (Aliphatic C-H str.), 1630, 1446 (Aromatic C=C ring str.), 1574 (C=N str.), 1350 (Aromatic C=N str.), 748 (C-Cl str.);

1H NMR (300 MHz, DMSO-d6) δ ppm: 7.00 (dd, 1H), 7.10 (dd, 1H), 7.20 (dd, 2H), 7.30 (d, 1H), 7.40 (d, 1H), 7.50 (s, 1H), 7.58 (d, 1H), 7.60 (d, 1H), 7.83 (dd, 1H), 7.84 (d, 1H), 8.01 (d, 1H), 9.23 (s, 1H); 13C NMR (75 MHz, DMSO-d6) δ ppm: 102.01, 111.12, 119.01, 120.18, 122.23, 123.71, 123.79, 125.20, 126.14, 127.42, 127.88, 128.60, 130.21, 130.30, 132.11, 134.09, 136.77, 144.34, 147.35, 149.42, 155.63, 160.14; EIMS (m/z): [M]+ 355.35, [M+1]+ 356.37, [M+2]+ 357.13; Fragments: 217.20, 189.33, 163.23, 138.23, 109.75, 27.17; Anal. calcd. for C22H16N3Cl: C, 74.26; H, 3.97; N, 11.81. Found: C, 74.25; H, 3.95; N, 11.84.

N-((1H-indolo[1,2-c]quinazolin-12-yl)methylene)-2-nitrobenzenamine (4a5)

Compound 3a (1g) was refluxed with 2-Nitroaniline (0.56 g).

(Yield: 1.18 g, 80%); M.p. 265-266 °C;

FT-IR (νmax, cm⁻¹) 3037 (Aromatic C-H str.), 2935 (Aliphatic C-H str.), 1611 (C=N str.), 1585,1415 (Aromatic C=C ring str.), 1525, 1322 (N=O str.), 1220 (C-N str.); 1H NMR (300 MHz, DMSO-d6) δ ppm: 7.00 (dd, 1H), 7.10 (dd, 1H),
7.40 (d, 1H), 7.50 (m, 3H), 7.58 (dd, 1H), 7.60 (d, 1H), 7.70 (dd, 1H), 7.83 (dd, 1H), 7.84 (d, 1H), 8.01 (d, 1H), 8.20 (d, 1H), 9.23 (s, 1H);

13C NMR (75 MHz, DMSO-d6) $\delta$ ppm: 102.05, 111.10, 119.04, 120.12, 122.25, 122.45, 123.29, 125.28, 126.12, 127.45, 127.86, 128.20, 128.61, 134.12, 136.23, 136.71, 141.92, 144.13, 144.56, 149.40, 155.93, 160.12;

EIMS (m/z): [M]+ 366.76, [M+1]+ 367.36; Fragments: 217.16, 189.37, 163.44, 149.73, 109.25, 27.10; Anal. calcd. for C22H14N4O2; C, 72.12; H, 3.85; N, 15.29. Found: C, 72.10; H, 3.82; N, 15.33.

$N$-((1H-indole [1,2-c]quinazoline-12-yl)methylene)-3-nitrobenzenamine (4a6)

Compound 3a (1g) was refluxed with 3-Nitroaniline (0.56 g).

(Yield: 1.19 g, 81 %); M.p. 264-265 °C;

FT-IR ($\nu_{\text{max}}$, cm$^{-1}$) 3051 (Aromatic C-H str.), 2935 (Aliphatic C-H str.), 1635 (C=N str.), 1585,1419 (Aromatic C=C ring str.), 1508, 1360 (N=O str.), 1174 (C-N str.); $^1$H NMR (300 MHz, DMSO-d6) $\delta$ ppm: 7.00 (dd, 1H), 7.10 (dd, 1H), 7.40 (d, 1H), 7.50 (m, 2H), 7.58 (dd, 1H), 7.60 (d, 1H), 7.70 (d, 1H), 7.83 (dd, 1H), 7.84 (d, 1H), 8.01 (d, 1H), 8.20 (m, 2H), 9.23 (s, 1H);

13C NMR (75 MHz, DMSO-d6) $\delta$ ppm: 102.12, 111.16, 117.11, 119.27, 119.61, 120.71, 122.77, 125.23, 127.42, 127.83, 128.44, 128.64, 131.03, 134.39, 136.54, 144.67, 149.42, 149.56, 149.92, 155.90, 160.12;

EIMS (m/z): [M]+ 366.36, [M+1]+ 367.39; Fragments: 217.16, 189.36, 163.17, 149.33, 109.27, 27.10; Anal. calcd. for C22H14N4O2; C, 72.12; H, 3.85; N, 15.29. Found: C, 72.09; H, 3.81; N, 15.32.

$N$-((1H-indole[1,2-c]quinazoline-12-yl)methylene)-4-nitrobenzenamine (4a7)

Compound 3a (1g) was refluxed with 4-Nitroaniline (0.56 g).

(Yield: 1.19 g, 81 %); M.p. 270-271 °C;

FT-IR ($\nu_{\text{max}}$, cm$^{-1}$) 3080 (Aromatic C-H str.), 2958 (Aliphatic C-H str.), 1685 (C=N str.), 1602,1421 (Aromatic C=C ring str.), 1554, 1326 (N=O str.), 1292 (C-N str.); $^1$H NMR (300 MHz, DMSO-d6) $\delta$ ppm: 7.00 (dd, 1H), 7.10 (dd, 1H), 7.40 (d, 1H), 7.50 (m, 2H), 7.58 (dd, 1H), 7.60 (d, 1H), 7.70 (d, 1H), 7.83 (dd, 1H), 7.84 (d, 1H), 8.01 (d, 1H), 8.20 (2H), 9.23 (s, 1H);

13C NMR (75 MHz, DMSO-d6) $\delta$ ppm: 102.11, 111.12, 119.04, 120.13, 122.20, 122.44, 122.79, 123.20, 123.24, 125.22, 126.18, 127.40, 127.81, 128.62, 134.01, 136.79, 144.47, 146.92, 149.45, 155.12, 155.91, 160.13;

EIMS (m/z): [M]+ 366.76, [M+1]+ 367.16; Fragments: 217.13, 189.37, 163.47, 149.27, 109.64, 27.14; Anal. calcd. for C22H14N4O2; C, 72.12; H, 3.85; N, 15.29. Found: C, 72.11; H, 3.87; N, 15.28.

$N$-((1H-indole[1,2-c]quinazoline-12-yl)methylene)-4-fluorobenzenamine (4a8)

Compound 3a (1g) was refluxed with 4-Fluoroaniline (0.44 g).

(Yield: 1.17 g, 86 %); M.p. 245-246 °C;

FT-IR ($\nu_{\text{max}}$, cm$^{-1}$) 3075 (Aromatic C-H str.), 2925 (Aliphatic C-H str.), 1621, 1454 (Aromatic C=C ring str.), 1555 (C=N str.), 1325 (Aromatic C-N str.), 1292 (C-F str.); $^1$H NMR (300 MHz, DMSO-d6) $\delta$ ppm: 7.00 (dd, 1H), 7.10 (dd, 1H), 7.20 (dd, 2H), 7.40 (d, 1H), 7.50 (s, 1H), 7.58 (dd, 1H), 7.60 (d, 1H), 7.83 (dd, 1H), 7.84 (d, 1H), 8.01 (d, 1H), 9.23 (s, 1H);

13C NMR (75 MHz, DMSO-d6) $\delta$ ppm: 102.02, 111.15, 116.81, 116.84, 119.03, 120.21, 122.29, 123.24, 123.48, 125.25, 126.18, 127.42, 127.81, 128.65, 134.02, 136.71, 144.49, 144.67, 149.49, 155.91, 160.12, 161.4;

EIMS (m/z): [M]+ 339.39, [M+1]+ 340.07; Fragments: 217.27, 189.24, 163.42, 122.42, 109.49, 27.14; Anal. calcd. for C22H14N3F; C, 77.86; H, 4.16; N, 12.38. Found: C, 77.84; H, 4.19; N, 12.35.

$N$-((1H-indole[1,2-c]quinazoline-12-yl)methylene)-4-bromobenzenamine (4a9)

Compound 3a (1g) was refluxed with 4-Bromoaniline (0.69 g).

(Yield: 1.37 g, 85 %); M.p. 245-246 °C;

FT-IR ($\nu_{\text{max}}$, cm$^{-1}$) 3051 (Aromatic C-H str.), 2940 (Aliphatic C-H str.), 1609,1458 (Aromatic C=C ring str.), 1573 (C=N str.), 1327 (Aromatic C-N str.), 551 (C-Br str.); $^1$H NMR (300 MHz, DMSO-d6) $\delta$ ppm: 7.00 (dd, 1H), 7.20 (dd, 2H), 7.30 (d, 1H), 7.40 (d, 3H), 7.50 (s, 1H), 7.58 (dd, 1H), 7.60 (d, 1H), 7.83 (dd, 1H), 7.84 (d, 1H), 8.01 (d, 1H), 9.23 (s, 1H);
The antibacterial potential of all compounds was tested and compared with ciprofloxacin using agar well diffusion method. Activity was performed against gram negative bacteria *Escherichia coli* and gram positive bacteria *Bacillus subtilis*. Test microorganisms were obtained from Microbiology Laboratory, National JALMA Institute for Leprosy & Other Mycobacterial Diseases, Agra, India. Synthesized compounds were not shown significant antibacterial activity at the concentration range of 10 to 30 μg/μL. So, the higher concentrations of compounds were used to evaluate antibacterial efficacy. Solution with concentration of 100 μg/μL and 150 μg/μL of each test compound was prepared in Dimethylsulfoxide (DMSO). All materials used were sterilized. The microorganisms were grown in nutrient broth at 37 °C for 24 h. Nutrient agar was melted on a water bath and cooled to 45 °C. Then it was shook gently for uniform cooling. Each culture (1.0 ml) was inoculated aseptically and then it was mixed by gentle shaking and then poured into the already sterilized petridishes. Then the material was allowed to settle for 1–2 h and then solid medium was cut to make wells of 7 mm. A solution of each compound was added to each of these wells. Then these plates were incubated at 37 °C for 24 h. After the time of incubation, zone of inhibition around each of these wells was measured in millimeters. DMSO was used as a control. Ciprofloxacin was used as a reference standard [36].

### 4.3. Antioxidant activity

#### 4.3.1. DPPH radical scavenging assay

This assay is a standard method for the evaluation of antioxidant activity of compounds. Free radical scavenging ability of synthesized compounds was compared with ascorbic acid, which is a standard antioxidant. To evaluate antioxidant activity of compounds, 0.1 mM solution of DPPH was prepared by dissolving 1.9 mg

---

**Synthesis and biological activity of novel indolo[1,2-c]quinazoline derivatives**

*Dixit et al.*

Journal of Research in Pharmacy

Research Article

https://doi.org/10.12991/jrp.2019.166

J Res Pharm 2019; 23(3): 584-595
DPPH in methanol. To form the free radicals, solutions were kept in darkness for half an hour. Sample solutions of different concentrations were prepared (10, 20, 30, 40 and 50 μg/ml). Solutions of same concentrations were prepared with ascorbic acid and they were used as standard. 1 ml of solution of each test compound was added with same volume of DPPH solution, mixed vigorously and then kept in dark room for half an hour. Absorbance of all solutions was measured at 517 nm. Procedure was performed in triplicate manner (n=3) and the average of three readings with standard deviation was shown in results. Same procedure was done with the ascorbic acid solutions. Percent scavenging was calculated using equation 1 [37].

\[
\% \text{ inhibition} = \frac{\text{Absorbance of control} - \text{Absorbance of sample}}{\text{Absorbance of control}} \times 100 \\
\text{(Eq. 1)}
\]

4.3.2. \(H_2O_2\) radical scavenging activity

In this study hydrogen peroxide was used to form hydroxyl radicals. Standard and sample solutions were prepared as above and concentrations of hydroxyl radicals were evaluated at 230 nm [38]. Procedure was performed in triplicate manner and the average of three readings with standard deviation was shown in results. Percent inhibition (or % scavenging) activity was calculated by using equation 1.

Acknowledgements: Authors would like to thank management of Rajiv Academy for Pharmacy, Mathura for providing research facilities. IIT, Delhi is acknowledged for providing the spectral data of the synthesized compounds. National JALMA Institute for Leprosy & Other Mycobacterial Diseases, Agra is acknowledged for providing bacterial cultures.

Author contributions: Concept – A.D., D.P., G.K.S.; Design – A.D., D.P., G.K.S.; Supervision – G.K.S. Resource – A.D., D.P., G.K.S.; Materials – A.D., D.P., G.K.S.; Data Collection and/or Processing – A.D.; Analysis and/or Interpretation – A.D.; Literature Search – A.D.; Writing – A.D.; Critical Reviews A.D., D.P., G.K.S.

Conflict of Interest: Authors have no conflict of interest.

REFERENCES

[1] Somei M, Yamada F. Simple indole alkaloids and those with a nonrearranged monoterpoid unit. Nat Prod Rep. 2003; 20: 216-242. [CrossRef]

[2] Gupta L, Talwar A, Chauhan PMS. Bis and tris indole alkaloids from marine organisms: new leads for drug discovery. Curr Med Chem. 2007; 14: 1789-1803. [CrossRef]

[3] Xu H, Lv M. Developments of indoles as anti-HIV-1 inhibitors. Curr Pharm Des. 2009; 15: 2120-2148. [CrossRef]

[4] Ran J, Huang N, Xu H, Yang Y, Lv M, Zheng YT. Anti HIV-1 agents 5: Synthesis and anti-HIV-1 activity of some \(N\)-arylsulfonyl-3-acetylindroles. Bioorg Med Chem Lett. 2010; 20: 3534-3536. [CrossRef]

[5] Ghosh AK, Gong G, Grum-Tokars V, Mulhearn DC, Baker SC, Coughlin M, Prabhakar BS, Sleeman K, Johnson ME, Mesecar AD. Design, synthesis and antiviral efficacy of a series of potent chloropyridyl ester-derived SARS-CoV 3CLpro inhibitors. Bioorg Med Chem Lett. 2008; 18: 5684-5688. [CrossRef]

[6] Williams JD, Chen JI, Drach JC, Townsend LB. Synthesis and antiviral activity of 3-formyl- and 3-Cyano-2,5,6-trichloroindole nucleoside derivatives. J Med Chem. 2004; 47: 5766-5772. [CrossRef]

[7] Andreani A, Burnelli S, Granaiola M, Leoni A, Locatelli A, Morigi R, Rambaldi M, Varoli L, Landi L, Prata C, Berridge MV, Grasso C, Fiebig HH, Kelter G, Burger AM, Kunkel MW. Antitumor activity of bis-indole derivatives. J Med Chem. 2008; 51: 4563-4570. [CrossRef]

[8] Slater MJ, Baxter R, Bonser RW, Cockerill S, Gohil K, Parry N, Robinson E, Randall R, Yeates C, Snowden W, Walters A. Synthesis of \(N\)-alkyl substituted indolocarbazoles as potent inhibitors of human cytomegalovirus replication. Bioorg Med Chem Lett. 2001; 11: 1993-1995. [CrossRef]
[9] Mathada BSD, Mathada MBH. Synthesis and antimicrobial activity of some 5-substituted-3-phenyl-Nb-(Substituted-2-oxo-2H-pyrano[2,3-b]quinoline-3-carbonyl)-1H-indole-2-carboxyhydrazide. Chem Pharm Bull. 2009; 57: 557-560. [CrossRef]

[10] Gurkok G, Altanlar N, Suzen S. Investigation of antimicrobial activities of indole-3-aldehyde hydrazide/hydrazone derivatives. Chemotherapy. 2009; 55, 15-19. [CrossRef]

[11] Karah N, Gursoy A, Kandemirli F, Shvets N, Kaynak FB, Ozbay S, Kovalishyn V, Dimoglo A. Synthesis and structure-antituberculosis activity relationship of 1H-indole-2,3-dione derivatives. Bioorg Med Chem. 2007; 15: 5888-5891. [CrossRef]

[12] Dekker WH, Selling HA, Overeem JC. Structure-activity relationships of some antifungal indoles. J Agric Food Chem. 1975; 23: 785-791. [CrossRef]

[13] Whitehead CW, Whitesitt AA. Effects of lipophilic substituents on some biological properties of indoles. J Med Chem. 1974; 17: 1298-1304. [CrossRef]

[14] Malesani G, Chiarelotto G, Dallacqua F, Vedali D. Antimicrobial properties of some 3-acyl-4,7- disubstituted indoles. Farmaco. 1975; 30: 137-146.

[15] Donawade DS, Gadaginamath GS. Some electrophilic substitution reactions on 1-substituted-3-acetyl/carboxy-5-hydroxy-2-methylindole and antimicrobial activity of these new indole derivatives. Indian J Chem. 2005; 44B: 1679-1685.

[16] Tso tinis A, Varvaresou A, Calogeropoulou T, Siatra-Papastaikoudi T, Tiligada A. Synthesis and antimicrobial evaluation of indole containing derivatives of 1,3,4-triazole and their open-chain counterparts. Drug Res. 1997; 47: 307-310.

[17] Varvaresou A, Tsantili-Kakoulidou A, Siatra-Papastaikoudi T, Tiligada E. Synthesis and biological evaluation of indole containing derivatives of thiosemicarbazide and their cyclic 1,2,4-triazole and 1,3,4-thiadiazole analogs. Drug Res. 2000; 50: 48-54. [CrossRef]

[18] Macchia M, Manera C, Nencetti S, Rossello A, Broccoli G, Limonta D. Synthesis and antimicrobial activity of benzo[a]dihydrocarbazole and benzotetrahydrocyclohept[1,2]b]indole derivatives. Farmaco. 1996; 51: 75-78.

[19] Gadaginamath GS, Kavali RR. Synthesis and antimicrobial activity of novel 4H-pyrano[2,3-f]- indole derivatives. Indian J Chem. 1999; 38B: 178-182.

[20] Bhovi MG, Gadaginamath GS. 1, 3-Dipolaracycloaddition reactions: Synthesis and antimicrobial activity of novel 1-triazolylindole and 1-triazolylbenz-[g]indole derivatives. Indian J Chem. 2005; 44B: 1068-1073.

[21] Bast A, Haenen G, Doelman C. Oxidants and antioxidants: state of the art. Am J Med. 1991; 92 (Suppl. 3C): 2-13. [CrossRef]

[22] Bulkley GB. Free radicals and other reactive oxygen metabolites: Clinical relevance and the therapeutic efficacy of antioxidant therapy. Surgery. 1993; 113: 479-483.

[23] Halliwell B, Gutteridge M. Free radicals in biology and medicine, third ed. Oxford Science Publications. Oxford University Press. 1998.

[24] Sreejayan N, Rao MN. Free radical scavenging activity of curcuminoids. Drug Res. 1996; 46: 169-171.

[25] McCord JM. Human disease, free radicals, and the oxidant/antioxidant balance. Clin Biochem. 1993; 26: 351-357. [CrossRef]

[26] Cross CE, Vliet A, Neill ACO, Eiserich JP. Reactive oxygen species and the lung. Lancet. 1994; 344: 930-933. [CrossRef]

[27] Santrucek M, Krepelka J. Antioxidants from the aspect of their potential use in chemotherapy. Drugs Future. 1988; 37: 121-128. [CrossRef]

[28] Santrucek M, Krepelka J. Of particular interests are the potential protective effects of antioxidants on lipoproteins, since oxidized LDL is thought to be atherogenic. Drugs Future. 1988; 13: 973-996.

[29] Nikolic D, Breemen RB. DNA Oxidation Induced by Cyclooxygenase-2. Chem Res Toxicol. 2001; 14: 351-354. [CrossRef]

[30] Vapaatalo H. Free radicals and anti-inflammatory drugs. Med Biol. 1986; 64: 1-7.

[31] Halliwell B, Houltr JR, Blake DR. Oxidants, inflammation, and anti-inflammatory drugs. FASEB J. 1988; 2: 2867-2873. [CrossRef]
[32] Mouithys-Mickalad AML, Zheng SX, Deby-Dupont GP, Deby CM, Lamy MM, Reginster JY, Henrotin YE. *In vitro* study of the antioxidant properties of nonsteroidal anti-inflammatory drugs by chemiluminescence and electron spin resonance (ESR). Free Radic Res. 2000; 33: 607-621. [CrossRef]

[33] Turrens JF. Mitochondrial formation of reactive oxygen species. J Physiol. 2003; 552: 335-344. [CrossRef]

[34] Dedon PC, Tannenbaum SR. Reactive nitrogen species in the chemical biology of inflammation. Arch Biochem Biophys. 2004; 423: 12-22. [CrossRef]

[35] Billimoria AD, Cava MP. Chemistry of indolo[1, 2-c]quinazoline: An approach to the marine alkaloid Hinckdentine A. J Org Chem. 1994; 59: 6777-6782. [CrossRef]

[36] Uğur A, Mercimek B, Özlер MA, Aahın N. Antimicrobial effects of bis (2-imidazolinyl)-5,5V-dioxime and its mono- and tri-nuclear complexes. Transit Met Chem. 2000; 25: 421. [CrossRef]

[37] Malviya R, Sharma PK, Dubey SK. Antioxidant potential and emulsifying properties of kheri (*Acacia chundra*, Mimosaceae) gum polysaccharide. Marm Pharm J. 2017; 21(3): 701-706. [CrossRef]

[38] Ningsih IY, Zulaikah S, Hidayat MA, Kuswandi B. Antioxidant activity of various Kenitu (*Chrysophyllum cainito* L.) leaves extracts from Jember. Indonesia Agric Sci Procedia. 2016; 9: 378-385. [CrossRef]

This is an open access article which is publicly available on our journal’s website under Institutional Repository at http://dspace.marmara.edu.tr.